| INDEX | PAGE |
|---|---|
| Chair's report | 1-2 |
| Charitable activities review and Report ofthe Trustees |
3-13 |
| Independent auditor's report |
14- 17 |
| Statement offinancial activities | 18 |
| Balance sheet | 19 |
| Statement ofcash flows | 2P |
| Notes to the financial statements |
21-31 |
| Total | |||||||
|---|---|---|---|---|---|---|---|
| restricted and |
|||||||
| Unrestricted | Restricted | unrestricted | |||||
| funds | funds | Total funds | funds | ||||
| Votes | 2021f | 2021 | 2021f | 2020 | |||
| Income: | |||||||
| Investment income |
3 | 464,034 | 464,034 | 7I0,133 | |||
| Donations | 12 | 412,515 | 146,017 | 558,532 | 3l2,520 | ||
| Total income | 876,549 | 146,017 | 1,022,566 | l,022,653 | |||
| Expenditure: | |||||||
| Raising funds | |||||||
| Investment management Charitable activities |
costs | (105,$10) | (105,810) | (97„658) | |||
| Grant giving | (1,095,411) | (226,540) | (I+21,951) | (I, I20,523) | |||
| Total expenditure | (1,201,221) | (226,540) | (1,427,761) | (1.2 IS,I8 I) | |||
| Gains and losses on investments: | |||||||
| Gains ' (losses) on |
investments | 6,183,598 | 1,431 | 6,185,029 | (2,048,256) | ||
| Investment management |
costs | (70,670) | (70,670) | (106,583) | |||
| iVet gains / (losses) on investments |
6,112,928 | 1,431 | 6,114/59 | (2,154,839) | |||
| Net income I(expenditure) | «nd net | ||||||
| movement in funds |
5,788,256 | (79,092) | 5,709,164 | {2,350,367) | |||
| Reconciliation of Funds |
12 | ||||||
| Total funds brought | I'orward | 23,509,946 | 18,755 | 23,528,701 | 25,S79,068 | ||
| Total funds carried forward | 29,298,202 | (60,337) | 29,237,865 | 23,528,701 |
| Company no 166995 |
||||
|---|---|---|---|---|
| Note | 2021 | 2020 | ||
| f. | ||||
| Fixed assets | ||||
| investments | 31,514,602 | 26,013,363 | ||
| Current assets | ||||
| Debtors | 7 | 103,102 | 16,682 | |
| Cash at bank and in | hand | 8 | 685,421 | 591,263 |
| Total current assets | 788,523 | 607,945 | ||
| Liabilities | ||||
| Creditors: amounts | falling due within one year | {1,7S8,452) | (1,257,054) | |
| Net current liabilities |
(999,929) | {649,109) | ||
| Total assets less current liabilities | 30,514,673 | 25,364,254 | ||
| Creditors: amounts | falling due aAer more than one year | 10 | (1,276,808) | (1,835,553} |
| Net assets | 29,237,865 | 23,528,701 | ||
| The funds ofthe charity | 12 | |||
| Unrestricted income |
funds | 29/98,202 | 23,509,946 | |
| Restricted income funds |
(60,337) | 18,.755 | ||
| Total charity funds |
29+37,865 | 23,528,701 |
| Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| restricted and |
||||||||
| Unrestricted | Restricted | unrestricted | ||||||
| funds | funds | Total funds | funds | |||||
| Notes | 2021 | 2020 | ||||||
| Cash flows from operating | activities: | |||||||
| Net cash (used in) / provided | by | |||||||
| operating activities |
14 | (980/66) | 81,266 | (899,100) | (9226I5) | |||
| Cash flows from investing | activities: | |||||||
| Dividends and interest from Purchase ofinvestments {Purchase) .' disposal ofcash |
investments | 464,034 (7,525,296) |
464,034 (7,525,296) |
710,)33 {5,I I l,779) |
||||
| investments Proceeds from disposal |
ofinvestments | 254,187 7,929,553 |
254,187 7,929,553 |
(6,879) 5,502, I67 |
||||
| Investment management |
costs | (129,220} | (129320) | (138,574) | ||||
| Net cash provided by |
investing | |||||||
| activities | 993,258 | 993,258 | 955,068 | |||||
| Change in cash in the | year | 12,892 | 81,266 | 94,158 | 32,453 | |||
| Cash at the beginning ofthe | year | 572,508 | IS,?55 | 591,263 | 558,8IO | |||
| Cash at the end ofthe | year | 585,400 | 100,021 | 685,421 | 591,263 |
| Investment income comprises |
income from: | 2021 | 2020f |
|---|---|---|---|
| Dividends - listed UK equities |
and bonds | 118,721 | 252,129 |
| Dividends —overseas equities |
and bonds | 126,660 | 142,303 |
| Interest from UK cash deposits | 4,701 | 4,416 | |
| Other interest | 357 | 4,090 | |
| Income from other UK investments | 198,023 | 290,841 | |
| Income from other overseas investments | 15,572 | 16,354 | |
| 464,034 | 710,133 |
| 2021 | '2020 | ||||
|---|---|---|---|---|---|
| f | |||||
| Travel expenses | for the | Gimach | Partnership | 163 | 1,031 |
| Office expenses: | |||||
| The Gimach | Partnership | 1,942 | 3,502 | ||
| Wood Professional | Services | and Support Ltd | 3,338 | ||
| 5,443 | 4,533 |
| 2021 | 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Grant | giving | may be summarised as follows: |
|||||||
| Grants | to Institutions: | ||||||||
| Medical research grants and fellowships | 1,054,482 | 791,737 | |||||||
| Medical treatment, health'wellbeing and |
training grants |
262,947 | 242,871 | ||||||
| Grants health, |
for buildings, facilities and equipment for medical treatment and ' wellbeing |
15,900 | |||||||
| 1,333@29 | 1,034,608 | ||||||||
| Grant funding | credited to expenditure in |
respect ofearlier years' grants | (148,191) | (52,429) | |||||
| Total Grants | to Institutions | 1,185,138 | 982,179 | ||||||
| Discount to present value on grants payable alter more than | one year | (31,000) | |||||||
| Governance costs |
52,042 | 48,848 | |||||||
| Other support costs | 115,771 | 89,496 | |||||||
| 1,321,951 | 1,120,523 | ||||||||
| K | |||||||||
| 2021 | |||||||||
| Grants to Institutions were awarded as follows: |
|||||||||
| M di | ir | r i rants and clio&vshi s: |
|||||||
| The Babraham Institute |
|||||||||
| Research using RNA sequencing to understand responses in older people |
poor vaccine | 37,965 | |||||||
| The University ofCambridge |
|||||||||
| Modelling obesity associated |
liver disease using stem cell | derived | |||||||
| hepatic organoids | 20,000 | ||||||||
| Research into the stem cells | used for cell-based | cartilage therapy | 93,160 | ||||||
| Use ofDeuterium Wletabolic |
Imaging to improve dementia |
diagnosis | 62,826 | ||||||
| Research into inflammatory | pathvvays in autoimmune disease |
168,458 | |||||||
| Research to improve speech |
perception for people with cochlear |
||||||||
| imp lants | 51,979 | ||||||||
| Research into the role ofspecialised pro-resolving mediators |
in COPD | 147,624 | |||||||
| Development oftreatments |
using MesEncymal | cells to moderate | |||||||
| excessive immune responses |
in patients with COVID-19 pneumonitis |
60,000 | |||||||
| Research into the immune pathways operating |
in patients | with | |||||||
| COVID-19 infections | 240,000 | ||||||||
| Research to improve the diagnosis ofneonatal |
seizures and | epilepsy | 210,435 | ||||||
| Research into Charcot-Marie-Tooth neuropathies and treatment |
IS4,378 | ||||||||
| Use ofbiomarkers to guide |
oesophageal neoplasia patient |
||||||||
| management | 191,270 | ||||||||
| Research ofgastrointestinal | dysfunction in Parkinson's Disease |
46,605 | |||||||
| Understanding the genetic alterations that cause lymphoma |
62,543 | ||||||||
| Research into endometrial dysfunction and cancer in obesity |
10,000 | ||||||||
| Research into DNA damage | response in neurodegenerative |
diseases | l88,976 | ||||||
| Research into mononuclear |
phagocyte subsets |
in Psoriatic | Arthritis | 70,000 | |||||
| Grant funding credited to expenditure in respect ofgrants |
made | in | |||||||
| earlier years | (126,886) | {32,152) | |||||||
| 927,596 | 72l,620 | ||||||||
| Page 25 |
| 2021 | 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Addenbrooke's Charitable Trust |
|||||||||
| Psychological support service |
during | the | COVID-19 pandemic | 40,000 | |||||
| Cambridge | & District Citizens Advice Bureau | ||||||||
| IT support for COVID-19 systems revisions |
5,000 | ||||||||
| Cambridge | Ethnic Community Forum |
||||||||
| Improving refugee and migrant |
women's | health | and well-being | ||||||
| through mobile arts |
50,000 | ||||||||
| CPSL Mind | |||||||||
| Mums Matter training courses |
29,730 | ||||||||
| Disability | Cambridgeshire | ||||||||
| Early intervention caseworker |
for mental | health | and autism clients | 10,000 | |||||
| Disability | Huntingdonshire | ||||||||
| Mind Matters project | 5,000 | ||||||||
| COVID-I 9 response project | 5,000 | ||||||||
| 5,000 | 5,000 | ||||||||
| Disability | Peterborough | ||||||||
| In depth casework support | 10,000 | ||||||||
| Peterborough Citizens Advice Bureau |
|||||||||
| StJohn 8c | Services at Peterborough Cavell Centre Red Cross Defence Medical Welfare Service |
10,000 | |||||||
| 20Twenty | Welfare support officer service Productions CIC |
for Addenbrooke's | 50,000 | ||||||
| Family learning project to increase social Versus Arthritis |
mobility | 27,000 | |||||||
| Living Well with Arthritis project Other institutional grants awarded for f,10,000or |
less: | 11,400 | |||||||
| Nineteen awards during the year to 3I |
March 2021 | 159,547 | |||||||
| Sixteen awards during the year |
to 3 I March 2020 | 93.l4 1 | |||||||
| 159,547 | 93,14 I | ||||||||
| Grants orbaildin s acilitiesande ni ment ormedicaltreatmentandhealtbl |
|||||||||
| ~ellbein: | |||||||||
| Institutional | grants awarded for KI0,000 |
or less: | |||||||
| Two awards during thc Icar to |
3 I ivlarch | 202 I | 15,900 | ||||||
| Grant «ndin credited to ev enditare in res ect o |
rants madein | earlier | &ears: | ||||||
| Addenbrooke's Charitable Trust Arthur Rank Hospice Charity Institutions awarded grants off10,00Ci or less |
(21,305) | (14„732) (5,54» ) |
|||||||
| Total institutional grants |
1,I85,IM | 982,179 |
| Other UK, | ||||||
|---|---|---|---|---|---|---|
| overseas | ||||||
| Listed UK | Overseas | and multi- | ||||
| equities and | equities and | asset | UK cash | |||
| bonds | bonds | mvestments | deposits | Total | ||
| f. | ||||||
| Market value | at | |||||
| I April 2020 | 5,418,336 | 8,240,103 | 11,47~,956 | 880,968 | 26,013,363 | |
| Acquisitions | at cost | 404,197 | 6,988,606 | 154,407 | 7,547,210 | |
| Sales proceeds from disposals |
(3,044, 142) | (4,130,026) | (755,385) | (7,929,553) | ||
| Movement in |
cash | |||||
| deposits | (254,187) | (254,187) | ||||
| Net gain ' (loss) on |
||||||
| disposai and revaluation' |
902,150 | 3,371,427 | 1,864,192 | 6,137,769 | ||
| Market value at 31 iVlarch 2021 |
35680,541 | 14&470,110 | 12,737,170 | 626,781 | 31,514,602 | |
| Historical cost at 31 March 2021 |
3,'50076 | I I,l89 470 | l0 40I,484 | 626 78 l | 25,567 8 l I |
| Unrestricted | Restricted | |||
|---|---|---|---|---|
| funds | funds | Total | ||
| Cash | at I April 2020 | 572,508 | I8,755 | 59l,263 |
| Cash | flows | 12,892 | 81,266 | 94,I58 |
| Cash | at 3 I March 202 I | 585,400 | 100,021 | 685,421 |
| 2021 | 2020 | |||
|---|---|---|---|---|
| Trade Other Grants |
creditors creditors pal able |
and accruals | 11,587 58,307 l,7 I8,558 |
I3,649 70,870 I,172,535 |
| l,788,452 | I,257,054 |
| 2021 | 2020 | ||
|---|---|---|---|
| Grants | payable | 1,276,808 | l,835,553 |
| Grants | payable at I April 2020 |
|||
|---|---|---|---|---|
| Grants Grant |
in the year funding unused and written |
back | 3,008,088 1333,329 |
|
| Discount to present value on grants Grants paid in the year |
payable | aAer more than one year | (148,191) (31,000) {{,{66,{{60) |
|
| Grants | payable at 3I March 2021 |
2,995,366 |
| Net gains I | ||||||
|---|---|---|---|---|---|---|
| For the year ended 31 | Funds at | (losses) on | Funds at | |||
| March 2021: | I April | Income | Expendituref | investmentsf | 31March | |
| Unrestricted funds |
23,509,946 | 876,549 | (1,201,221} | 6,112,928 | 29,298,202 | |
| Restricted funds: |
||||||
| Mental health | support | 18,755 | (18,755) | |||
| James Bradfield | ||||||
| Memorial Award |
146,017 | (207,785} | 1,431 | 60,337} | ||
| Total charitable | funds | 23,528,701 | 1,022,566 | (1,427,761) | 6,114+59 | 29,237,865 |
| Net gains I | ||||||
| For the year ended | Funds at | (losses} on | Funds at | |||
| 31March 2020: | I Aprilf | Incomef | Expenditure | investments | 31 March | |
| Unrestricted funds |
25,860,313 | 1.022,653 | (l,218„1811 | (2,154,839) | 23,509,946 | |
| Restricted funds |
18,755 | 18,755 | ||||
| Total charitable | ||||||
| funds | 25,879,068 | 1,022,653 | (1,218,181) | (2,154,839) | 23+28,701 |
| Liabilities | Liabilities | |||||
|---|---|---|---|---|---|---|
| falling due | falling due | |||||
| Fixed | Current | within one |
after more | |||
| At 31March 2021: | assets | assets f, |
year | than one year | Totalf | |
| Unrestricted | funds | 31,491,257 | 646,415 | (1,744,176) | (1,095,294} | 29,298,202 |
| Restricted | funds | 23,345 | 142,108 | (44,276} | 181,514} | (60,337) |
| Total | 31,514,602 | 788,523 | (1,188,452) | (1,276,808) | 29,237,865 |
| Liabilities | Liabilities | |||||
|---|---|---|---|---|---|---|
| falling due | falling due | |||||
| Fixed | Current | within one | after more | |||
| At 31 March 2020: | assets | assets | year | than one year | Total | |
| f. | ||||||
| Unrestricted | funds | 26,013,363 | 589,190 | (1,257,054) | {1,835,553) | 23,509,946 |
| Restricted | funds | 18,755 | 18,755 | |||
| Total | 26,013,363 | 607,945 | (1357,054) | (1,835,553) | 23,528,701 |
| Iotal | ||||||||
|---|---|---|---|---|---|---|---|---|
| restricted and |
||||||||
| I'tlrestricted | Restricted | unrestricted | ||||||
| funds | funds | Total funds | funds | |||||
| 2021 | 2021 | 2021 | 2020 | |||||
| Net income | / (expenditure) | for the year | 5;/88,256 | {79,092) | 5,709,164 | (2,350,367) | ||
| Adjustments | for: | |||||||
| (Gains) | losses on investments | (6,183,598) | {1,431) | (6,185,029) | 2,048,256 | |||
| Donated | investments | (21,914) | (21,914) | |||||
| Dividends | and interest from investments |
(464,034) | (464,034) | (710,133) | ||||
| Investment | mana.tement costs | 176,480 | 176,480 | 204,241 | ||||
| {Increase) | decrease | in debtors | (44333) | (42,087) | i86,420) | 45,141 | ||
| {Decrease) | increase | in creditors | {15,225) | 600 | {14,625) | 6,668 | ||
| Increase | (decrease) | in grants | payable | {237,912} | 225,190 | {12,722) | {166,421) | |
| Net cash | used in operating | activities | (980,366) | 81,266 | {899,100) | (922,615) |